Permanent J-Code from CMS aims to streamline reimbursement and broaden patient access for its graft-versus-host disease treatment.
Analyst confidence swells following positive FDA alignment on the company's pivotal gene therapy trial for Rett Syndrome.
Genentech's Tecentriq combination therapy is the first maintenance treatment for extensive-stage small cell lung cancer, a significant advance in a hard-to-treat disease.
Warren Buffett's firm deepens its investment in the energy giant with an all-cash deal for its chemical division.
All-stock deal aims to create a diversified leader in the semiconductor sector, targeting high-growth AI and power device markets.
Regulators express significant doubts over the company's lead drug candidate, avacopan, sparking a massive investor sell-off.
The deal will create a combined semiconductor equipment firm, but investors react cautiously to the terms, sending Axcelis stock down 3.4%.
Deal would be one of the largest in the utility sector, driven by surging power demand from AI and data centers.